S462Homo sapiens (Human)Cancer cell line
Also known as: Patient 6 cell line
🤖 AI SummaryBased on 6 publications
Quick Overview
Human cell line derived from malignant peripheral nerve sheath tumor, used in cancer research.
Detailed Summary
The S462 cell line is a human-derived cell line established from a malignant peripheral nerve sheath tumor (MPNST). It is utilized in research to study the molecular mechanisms and therapeutic strategies for MPNST, a rare and aggressive soft tissue sarcoma. The cell line has been characterized in multiple studies for its genetic and molecular profiles, including alterations in tumor suppressor genes and oncogenes. Research involving S462 has explored its response to various therapeutic agents, including HDAC inhibitors and targeted therapies, highlighting its utility in preclinical drug testing and understanding tumor biology. The cell line is also used to investigate the role of specific genes and pathways in tumor progression and resistance to treatment.
Research Applications
Cancer researchDrug screeningMolecular mechanisms of tumor progressionTherapeutic target identification
Key Characteristics
Expresses EGFR and erbB2Genetic alterations in tumor suppressor genes (e.g., NF1, TP53)Response to HDAC inhibitors and targeted therapiesUsed in preclinical studies for MPNST
Generated on 6/18/2025
Basic Information
| Database ID | CVCL_1Y70 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Thigh[UBERON:UBERON_0000376] |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Female |
| Subtype Features | NF1_Mutant |
Disease Information
| Disease | Neurofibromatosis type 1 |
|---|---|
| Lineage | Peripheral Nervous System |
| Subtype | Malignant Peripheral Nerve Sheath Tumor |
| OncoTree Code | MPNST |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-002693_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg110Pro (c.329G>C) | Heterozygous | - | from parent cell line S462 |
| MutationSimple | NF1 | p.Tyr2285Ter (c.6792C>A) | Heterozygous | - | from parent cell line S462 |
| Gene deletion | TP53 | - | Homozygous | 2 out of 3 copies | from parent cell line HL-60 |
| Gene deletion | NF1 | - | Heterozygous | Somatic LOH | PubMed=15207265 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X
CSF1PO
12,13
D13S317
12
D16S539
13
D18S51
16
D19S433
14
D21S11
29,31
D2S1338
23
D3S1358
14,17
D5S818
12,13
D7S820
8,10
D8S1179
10,12
FGA
20
Penta D
9,11
Penta E
11
TH01
8
TPOX
8
vWA
19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Genetics of human malignant peripheral nerve sheath tumors.";
Pemov A., Li H., Presley W., Wallace M.R., Miller D.T.
Neurooncol. Adv. 2:i50-i61(2020).
Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
Lothe R.A.
Mol. Oncol. 11:1156-1171(2017).
Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.
Mautner V.-F., von Deimling A.
PLoS ONE 8:E57152-E57152(2013).
Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors.
Mautner V.-F., Rabkin S.D., Demestre M.
PLoS ONE 6:E21099-E21099(2011).
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Lev D.C.
Cancer Res. 71:185-196(2011).
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
Mautner V.-F., Schildhaus H.-U., von Deimling A.
Neuro-oncol. 10:946-957(2008).
Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids.
Mautner V.-F., Kindler-Rohrborn A., Kurtz A.
Oncogene 24:2367-2374(2005).